Biogen Stock News

Are we in for another winter surge? Has Biogen bottomed out? And can Covid-19 pills change the course of the pandemic? All that and more on the latest episode of…

DUBLIN, Nov. 18, 2021 /PRNewswire/ -- The "Global Auto Injector Market Outlook 2030" report has been added to ResearchAndMarkets.com''s offering. The market is estimated to garner a revenue of close to USD 11350 Million by the end of 2030, up from a revenue of about USD 3120 Million in the

Related Stocks: MSFT , TJX , CNI , TDY , MLM , CRM , AZN , AIG , DE , ICE , FITB , GM , GOOGL , PYPL , AYI , FB , BIIB , HOG ,

Biogen's (BIIB) regulatory application seeking approval for its Alzheimer's drug, Aduhelm, in Europe hits setback as it receives negative trend vote from the CHMP.

Wall Street analysts expect that Biogen Inc. (NASDAQ:BIIB) will post earnings per share of $3.39 for the current fiscal quarter, according to Zacks Investment Research. Thirty One analysts have provided estimates for Biogens earnings. The highest EPS estimate is $5.01 and the lowest is $2.65. Biogen posted earnings per share of $4.58 in the same []

Creative Financial Designs Inc. ADV grew its position in shares of Biogen Inc. (NASDAQ:BIIB) by 11.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,405 shares of the biotechnology companys stock after purchasing an additional 862 shares during the []

(RTTNews) - Shares of Biogen Inc. (BIIB) are down on Wednesday after the advisory committee of the European Medicines Agency recommended a "negative trend vote" for the company''s Alzheimer''s therapy drug Aducanumab. The "negative trend vote" by the EU''s Committee for Medicinal Products for Human Use comes after an oral explanation was

Wall Street is quickly discounting the possibility Biogen''s Alzheimer''s drug Aduhelm will generate revenues from the vast European market.

Global Trust Asset Management LLC reduced its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 25.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 697 shares of the biotechnology companys stock after selling 241 shares during the quarter. Global Trust []

The drug, Aduhelm, has been mired in controversy since it was in approved in the United States in June.

The European Commission (EC) has given its green light to Biogen, Inc. (BIIB) to market its multiple sclerosis (MS) treatment Vumerity (diroximel fumarate) The post Biogen Gets EU Marketing Approval for MS Treatment Vumerity appeared first on Smarter Analyst .

Bruton Tyrosine Kinase (BTK) Inhibitors Market Report for Forecast Period 2021-2027: The report presents the prevailing drivers, restraints, opportunities, and current trends in the Bruton Tyrosine Kinase (BTK) Inhibitors industry. The Bruton Tyrosine Kinase (BTK) Inhibitors Market report highlights in-depth

A European Medicines Agency panel notified Biogen that its Alzheimer’s treatment, Aduhelm, is unlikely to win approval.